Drug Combination Details
| General Information of the Combination (ID: C55665) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
|
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [3] | |||
|
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [4] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [5] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| HGC-27 | CVCL_1279 | Gastric carcinoma | Homo sapiens | |||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Harvested GC cells were washed in serum-free DMEM, suspended in 100 uL PBS, and implanted subcutaneously into the dorsal area of the nude mice. | |||||
| Experimental
Result(s) |
TQ significantly augments cisplatin-induced anti-tumor effects on gastric cancer both in vitro and in vivo, through inhibiting PI3K/AKT signaling pathway, activating the mitochondrial pathway, and down-regulating P-glycoprotein by up-regulating PTEN gene. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | COL11A2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | H2AFX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MIB1 | Molecule Info | |||
| Down-regulation | Expression | MKI67 | Molecule Info | |||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| NCI-ADR-RES | CVCL_1452 | Ovarian cancer | Homo sapiens | |||
| ID8-NGL | Ovarian cancer | Rattus norvegicus | ||||
| In-vivo Model | Wild-type C57BL/6 mice were injected intra-peritoneally (IP) with 1* 107 ID8-NGL cells suspended in 200 ul sterile PBS. | |||||
| Experimental
Result(s) |
Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. | |||||
| Experiment 3 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | UM-SCC-14C | CVCL_7721 | Mouth squamous cell carcinoma | Homo sapiens | ||
| OEC | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
Equitoxic combination of TQ and CDDP showed additive to synergistic interaction against both UMSCC-14C and OEC cells. | |||||
| Experiment 4 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | DDIT3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HSPA5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TRIM26 | Molecule Info | |||
| In-vivo Model | The mice modle was established by diethylnitrosamine/carbon tetrachloride-induced liver tumorigenesis in adult male Wistar albino rats. | |||||
| Experimental
Result(s) |
Thymoquinone potentiated the anticancer effect of cisplatin on hepatic tumorigenesis by modulating tissue oxidative stress and endoplasmic GRP78/CHOP signaling. | |||||
| Experiment 5 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | COL11A2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | |||
| Experimental
Result(s) |
TQ synergistically improves the anti-cancer activity of DDP, and loss of p53 sensitizes HCC cells to TQ-induced apoptosis. | |||||
| Experiment 6 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H146 | CVCL_1473 | Lung small cell carcinoma | Homo sapiens | |||
| In-vivo Model | Xenografts were obtained by injecting NCI-H460 2*106 cells subcutaneously into the right flank of each female SCID mice (age 5-6 weeks old). | |||||
| Experimental
Result(s) |
Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H146 | CVCL_1473 | Lung small cell carcinoma | Homo sapiens | |||
| In-vivo Model | Xenografts were obtained by injecting NCI-H460 2 * 106 cells subcutaneously into the right flank of each mouse. | |||||
| Experimental
Result(s) |
Combination of TQ and CDDP was well tolerated and significantly reduced tumor volume and tumor weight without additional toxicity to the mice. | |||||
